Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population
Open Access
- 10 January 2022
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 167, 98-103
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Pfizer Inc Boulder
This publication has 13 references indexed in Scilit:
- Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected AmyloidosisJACC, 2020
- Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac AmyloidosisCirculation: Heart Failure, 2019
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilizationJournal of Nuclear Cardiology, 2019
- Screening for Transthyretin Amyloid Cardiomyopathy in Everyday PracticeJACC: Heart Failure, 2019
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyJACC, 2019
- Transthyretin Amyloid CardiomyopathyJACC, 2019
- Tafamidis for Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2019
- Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisCirculation, 2016
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011